483
Hagop M. Kantarjian, M.D.Hagop M. Kantarjian, M.D. – FDA 483, May 5, 2017
Record Details
An FDA inspection of Hagop M. Kantarjian, M.D. in Houston, TX, identified significant deficiencies in the conduct of clinical trials. Observations included the improper documentation of informed consent, where forms were not dated by subjects, and the failure to report adverse experiences to the study sponsor in a timely manner as required by protocol and regulations.
View Company Profile
ID · ede3cc71-0ef1-46b5-908a-e128be222fff
Other documents for Hagop M. Kantarjian, M.D.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.